Clinical Trials Directory

Trials / Not Yet Recruiting

Not Yet RecruitingNCT07452341

Effect of Virtual Reality on Depression in Adolescent Females

Status
Not Yet Recruiting
Phase
N/A
Study type
Interventional
Enrollment
48 (estimated)
Sponsor
Cairo University · Academic / Other
Sex
Female
Age
13 Years – 18 Years
Healthy volunteers
Not accepted

Summary

The purpose of this study is to investigate the effect of virtual reality on depression in adolescent females.

Detailed description

Depression is most commonly found in adolescents and large percentage of them don't receive management. People with depression usually experience at least five of the following 9 characteristics: (1) people feel sad and unhappy; (2) have less interest in doing things; (3) individuals do not follow a diet, but their weight losses are obvious; (4) their appetites change and their weight may increase; (5) they suffer insomnia or drowsiness; (6) some people have mental agitation; (7) they feel that life is meaningless, or they feel guilty; (8) they have difficulty concentrating; or (9) they have suicidal thoughts . Individuals who develop depression may have experienced an anxiety disorder earlier in life. Depression is most commonly found in adolescents and large percentage of them don't receive management The application of emerging technology in health promotion has generated substantial public interest. Among the emerging technologies that may potentially aid in the treatment of depression, virtual reality (VR) is the most exciting and technologically-advanced. A virtual environment provides a greater degree of control for the therapists to customize, reproduce, and tweak several treatment parameters according to the patient's needs.

Conditions

Interventions

TypeNameDescription
DEVICEVirtual reality headsetParticipants will use virtual reality glasses during treatment sessions for approximately 30 minutes per session, once per week for 8 weeks .
DRUGSelective serotonin reuptake inhibitors(SSRIs)All adolescent females in the control group will receive antidepressant drugs Selective serotonin reuptake inhibitors(SSRIs) for 8 weeks as described by the psychiatrist

Timeline

Start date
2026-08-01
Primary completion
2027-01-01
Completion
2027-02-01
First posted
2026-03-05
Last updated
2026-03-11

Source: ClinicalTrials.gov record NCT07452341. Inclusion in this directory is not an endorsement.